Navigation Links
GenVec Reports Fourth Quarter And 2012 Year-End Financial Results
Date:3/22/2013

GAITHERSBURG, Md., March 22, 2013 /PRNewswire/ -- Today GenVec, Inc. (NASDAQ: GNVC) announced financial results for the fourth quarter and year ended December 31, 2012.  For the year ended December 31, 2012, the Company reported a net loss of $14.1 million, or $1.09 per share, compared with a net loss of $7.4 million, or $0.58 per share, for the year ended December 31, 2011. GenVec ended the year with $15.3 million in cash, cash equivalents, and short-term investments. 

"In 2012 we continued to make progress in our hearing restoration program, partnered with Novartis, and advanced the development of our product pipeline and core technologies," stated Cynthia Collins , GenVec's President and CEO.  "Other changes implemented since my joining GenVec in May were reducing our workforce to preserve capital and discontinuing spending on non-funded programs.  We continue to seek sources of non-dilutive funding to advance our programs and to reduce expenses to preserve cash."

2012 and Recent Corporate HighlightsHearing Restoration

  • We extended our Research Collaboration and License Agreement with Novartis.  Under the extension, Novartis will fund research at GenVec through January 2014 to support its hearing loss and balance disorders program.
  • RSV Vaccine

  • GenVec conducted a successful pre-IND interaction with the U.S. Food and Drug Administration (FDA) to obtain guidance on the development plan for its vaccine against respiratory syncytial virus (RSV).  The outcome of the pre-IND interaction was obtaining clarification on the nonclinical, clinical, and chemistry, manufacturing, and control (CMC) requirements that need to be met in order to submit an acceptable IND.
     
  • GenVec received a grant of approximately $590,000 over two years from the Natio
    '/>"/>

  • SOURCE GenVec, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
    2. GenVec Appoints Cynthia Collins as President and CEO
    3. GenVec Reports Inducement Award
    4. GenVec Announces Conditional Approval of FMD Vaccine for Cattle
    5. GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012
    6. GenVec Reports Second Quarter 2012 Financial Results
    7. GenVec Reports Third Quarter 2012 Financial Results
    8. GenVec to Present at 25th Annual ROTH Conference
    9. GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013
    10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... LONDON , February 27, 2015 ... - new study showing you trends, R&D progress, and ... medicine heading? What are the commercial prospects for ... shows you potential revenues and other trends to 2025, ... ,s report lets you assess regenerative medicine : ...
    (Date:2/27/2015)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), ... for its first quarter ended December 31, 2014. ... 2014, revenue was $1,336,685. Operating expenses were $1,063,393.  Net ... share.  Covalon,s President and CEO, ... the significant progress we have made over the past ...
    (Date:2/27/2015)... , February 27, 2015 ... bahnbrechendes Überwachungssystem für kongestive Herzinsuffizienz (CHF) in ...     ... ein neuartiges Herzüberwachungssystem für Patienten mit kongestiver ... dass sie ein Finanzierungsvorhaben über 5 Mio. ...
    Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2
    ... 28, 2010 /PRNewswire-Asia/ -- Chindex International, Inc. ("Chindex") ... American provider of Western healthcare products and services ... Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"), a ... medicine and devices in China, today announced the ...
    ... that new in-demand ResearchInChina reports on China industries ... Beer Industry Report, 2009-2010 . The report discusses development of ... in China. The study provides data on sales volume and ... product features and marketing strategies. China ...
    Cached Medicine Technology:Chindex and Fosun Pharma Form Joint Venture 2Chindex and Fosun Pharma Form Joint Venture 3Chindex and Fosun Pharma Form Joint Venture 4Chindex and Fosun Pharma Form Joint Venture 5Topical China Industries Research Reports Published at MarketPublishers.com 2
    (Date:2/27/2015)... Hispanics develop alcoholic liver disease (ALD), ... 12 years earlier than Whites/Caucasians or African Americans, according ... , While previous research indicated that Hispanics tend to ... study -- published online in the journal Alcoholism: Clinical ... first to pinpoint racial and ethnic disparities in the ...
    (Date:2/27/2015)... Beverly Hills, CA (PRWEB) February 27, 2015 ... was in the air for those suffering from Sjögren’s ... had been discovered by researchers at the University of ... the next phase of research was to develop a ... to precisely detect the presence of new autoantibodies. Researchers ...
    (Date:2/27/2015)... Clinovo, a leading provider of cloud-based eClinical ... (EDC) at the CALBIO2015 conference taking place ... 3rd at Booth # 141. , ClinCapture ... edit-check builder allowing Clinical Trials Managers to create CRFs ... any programming experience. Clinovo’s new pricing model offers a ...
    (Date:2/27/2015)... (PRWEB) February 27, 2015 In honor of American ... Primary Care (CPC) South office, is offering tips on how to ... of death, but that doesn't mean people have to accept it ... some risk factors — such as family history, sex or age ... , Dr. Scott has six helpful tips to improve heart ...
    (Date:2/27/2015)... February 27, 2015 The federal court ... that allege use of the statin medication can increase ... issued a new order pertaining discovery in the cases ... Liebhard LLP comments. The Order, which was issued in ... February 25th, directs the parties to schedule certain witness ...
    Breaking Medicine News(10 mins):Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2Health News:Breakthrough Blood Test for Early Detection of Sjögren’s Syndrome Now Available 2Health News:Clinovo to Demo Its Self-Service, Cloud-Based EDC Solution at CALBIO2015 on March 2nd and 3rd, 2015 2Health News:Center for Primary Care Celebrates American Heart Month 2Health News:Center for Primary Care Celebrates American Heart Month 3Health News:Center for Primary Care Celebrates American Heart Month 4Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 2Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 3
    ... , ST. PAUL, Minn., Dec. 10 /PRNewswire-USNewswire/ -- ... their 6th annual blood drive event with the Minnesota Vikings ... at the St. Paul Donor Center (I-94 and Hwy. 280), ... cheerleaders scheduled to arrive around 2 PM. All presenting ...
    ... ... announces that, after a national search, the Board of Trustees of Abington Health voted to ... ... H. Durham, chairman, Board of Trustees of Abington Health and Abington Memorial Hospital, announces that, ...
    ... , ARLINGTON, Va., Dec. 10 Americans ... but are highly aware of the risks of not receiving care, ... Mental Illness (NAMI). , See full survey results at ... people of diverse communities. , Though depression is common and highly ...
    ... , Helps PSI, DFID and USAID highlight progress in ... 10 Emmy Award winning actress and PSI (Population Services ... and individuals who have contributed to the substantial decline in ... six years Zimbabwe has seen a dramatic reduction in the ...
    ... the emissions leaving a car tailpipe or factory smokestack affect ... the atmosphere. But until now, scientists have struggled to know ... once they leave their source, leading to models for predicting ... accurate. A major collaborative effort of more than ...
    ... Pennsylvania School of Medicine have developed a new model of ... molecule called Src kinase is activated in human skin-cancer samples. ... are activated in human squamous cell carcinomas of the skin. ... gene Fyn, a member of Src family of proteins, in ...
    Cached Medicine News:Health News:Minnesota Vikings Team With Memorial Blood Centers Again for Annual Blood Drive 2Health News:Abington Health Announces New President and CEO 2Health News:Abington Health Announces New President and CEO 3Health News:Depression Survey: Implications for Diverse Communities 2Health News:Emmy Award Winning Actress Debra Messing Visits Zimbabwe 2Health News:Emmy Award Winning Actress Debra Messing Visits Zimbabwe 3Health News:New approach to emissions makes climate and air quality models more accurate, major study finds 2Health News:New approach to emissions makes climate and air quality models more accurate, major study finds 3Health News:New model of skin cancer provides insights on second-most common type of cancer 2
    Ideal for abdominal and back procedures....
    Female High Waist Briefs...
    Provides upper and lower arm support. Extends to the lower arm and across the shoulders. Has two columns of hook & eye closure for added adjustability....
    Short-Sleeve Bolero for targeted compression in the upper arms, back and shoulder areas. Plush-shielded hook and eye front closure for comfort and convenient application....
    Medicine Products: